Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 5 | 2024 | 2480 | 1.110 |
Why?
|
| T-Lymphocytes | 10 | 2022 | 1678 | 0.880 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2021 | 12 | 0.790 |
Why?
|
| Oncolytic Virotherapy | 4 | 2021 | 84 | 0.790 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2021 | 108 | 0.770 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 27 | 0.760 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2021 | 49 | 0.750 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 479 | 0.720 |
Why?
|
| Caspase 9 | 4 | 2015 | 75 | 0.700 |
Why?
|
| Adenoviridae | 4 | 2021 | 637 | 0.680 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 497 | 0.620 |
Why?
|
| Immunotherapy | 5 | 2024 | 658 | 0.600 |
Why?
|
| Genetic Therapy | 3 | 2021 | 706 | 0.590 |
Why?
|
| Genetic Vectors | 5 | 2021 | 969 | 0.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 339 | 0.470 |
Why?
|
| Multiple Myeloma | 1 | 2016 | 171 | 0.470 |
Why?
|
| Gene Transfer Techniques | 2 | 2015 | 374 | 0.470 |
Why?
|
| Neoplasms | 3 | 2024 | 2753 | 0.420 |
Why?
|
| Oncolytic Viruses | 3 | 2021 | 72 | 0.410 |
Why?
|
| Lymphocyte Transfusion | 1 | 2012 | 58 | 0.400 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 386 | 0.380 |
Why?
|
| Apoptosis | 4 | 2021 | 1790 | 0.370 |
Why?
|
| Genes, Transgenic, Suicide | 3 | 2015 | 49 | 0.370 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2022 | 790 | 0.360 |
Why?
|
| Leukemia | 2 | 2011 | 375 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 1615 | 0.340 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2021 | 874 | 0.330 |
Why?
|
| Interleukin-15 | 1 | 2010 | 95 | 0.330 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 271 | 0.330 |
Why?
|
| Antigens, CD19 | 1 | 2010 | 177 | 0.320 |
Why?
|
| Antigen Presentation | 2 | 2024 | 107 | 0.310 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 3290 | 0.280 |
Why?
|
| Lymphoma | 1 | 2010 | 323 | 0.280 |
Why?
|
| Lymphocyte Activation | 4 | 2021 | 680 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 1192 | 0.260 |
Why?
|
| Mice, SCID | 7 | 2021 | 570 | 0.240 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 30 | 0.230 |
Why?
|
| Peptides | 2 | 2024 | 798 | 0.220 |
Why?
|
| Genetic Engineering | 2 | 2018 | 159 | 0.220 |
Why?
|
| Enzyme Activation | 2 | 2015 | 621 | 0.220 |
Why?
|
| Proteogenomics | 1 | 2024 | 70 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 71 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1022 | 0.210 |
Why?
|
| Mice | 12 | 2021 | 17546 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2011 | 506 | 0.200 |
Why?
|
| Humans | 23 | 2024 | 122296 | 0.190 |
Why?
|
| Animals | 15 | 2021 | 33721 | 0.190 |
Why?
|
| Gene Expression | 3 | 2015 | 1579 | 0.190 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2021 | 78 | 0.190 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 1677 | 0.190 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 26 | 0.190 |
Why?
|
| Mastectomy | 1 | 2021 | 62 | 0.190 |
Why?
|
| Helper Viruses | 1 | 2021 | 55 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 4282 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1247 | 0.180 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 34 | 0.180 |
Why?
|
| Interleukin-12 | 1 | 2021 | 118 | 0.180 |
Why?
|
| Radiotherapy | 1 | 2021 | 140 | 0.180 |
Why?
|
| Dependovirus | 1 | 2021 | 125 | 0.170 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 872 | 0.160 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 217 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 532 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 1008 | 0.150 |
Why?
|
| Genes, Reporter | 2 | 2015 | 384 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1227 | 0.140 |
Why?
|
| Transgenes | 2 | 2015 | 330 | 0.140 |
Why?
|
| Female | 8 | 2024 | 64883 | 0.140 |
Why?
|
| Glioma | 1 | 2021 | 495 | 0.130 |
Why?
|
| Tumor Microenvironment | 2 | 2021 | 548 | 0.130 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2021 | 262 | 0.130 |
Why?
|
| Fibrin | 1 | 2016 | 67 | 0.130 |
Why?
|
| Immune Tolerance | 1 | 2016 | 145 | 0.130 |
Why?
|
| Injections, Intralesional | 1 | 2015 | 48 | 0.130 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2015 | 20 | 0.130 |
Why?
|
| Glucuronidase | 1 | 2015 | 32 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 1118 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2015 | 768 | 0.120 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 187 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 217 | 0.120 |
Why?
|
| Boronic Acids | 1 | 2014 | 49 | 0.120 |
Why?
|
| Age Factors | 1 | 2021 | 2777 | 0.120 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 297 | 0.120 |
Why?
|
| Pyrazines | 1 | 2014 | 74 | 0.120 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2013 | 28 | 0.110 |
Why?
|
| Mutation | 2 | 2024 | 5734 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2015 | 192 | 0.110 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 237 | 0.100 |
Why?
|
| Neuroblastoma | 2 | 2014 | 511 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1222 | 0.100 |
Why?
|
| Virus Replication | 1 | 2015 | 603 | 0.100 |
Why?
|
| Receptors, IgE | 1 | 2011 | 10 | 0.090 |
Why?
|
| Coculture Techniques | 3 | 2021 | 235 | 0.090 |
Why?
|
| Time Factors | 1 | 2021 | 6182 | 0.090 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2011 | 58 | 0.090 |
Why?
|
| Models, Biological | 1 | 2016 | 1438 | 0.090 |
Why?
|
| Transplantation, Homologous | 1 | 2012 | 659 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 6291 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2010 | 78 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 184 | 0.080 |
Why?
|
| Immunophenotyping | 1 | 2010 | 333 | 0.080 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2009 | 22 | 0.080 |
Why?
|
| Interleukin-7 | 1 | 2009 | 43 | 0.080 |
Why?
|
| Gangliosides | 1 | 2009 | 64 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2011 | 295 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 99 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2021 | 285 | 0.070 |
Why?
|
| Melanoma | 2 | 2013 | 835 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2013 | 1520 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 375 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 609 | 0.060 |
Why?
|
| Aged | 1 | 2021 | 18785 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 156 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2021 | 15853 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 352 | 0.050 |
Why?
|
| Cell Line | 3 | 2015 | 2782 | 0.050 |
Why?
|
| Middle Aged | 1 | 2021 | 25640 | 0.050 |
Why?
|
| A549 Cells | 1 | 2021 | 45 | 0.050 |
Why?
|
| Viral Tropism | 1 | 2021 | 34 | 0.050 |
Why?
|
| Proteomics | 1 | 2024 | 475 | 0.050 |
Why?
|
| Adult | 1 | 2021 | 28733 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 812 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 267 | 0.040 |
Why?
|
| HLA-A2 Antigen | 2 | 2011 | 23 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 103 | 0.040 |
Why?
|
| HLA-A Antigens | 2 | 2011 | 35 | 0.040 |
Why?
|
| K562 Cells | 2 | 2011 | 95 | 0.040 |
Why?
|
| Interleukin-2 | 2 | 2011 | 237 | 0.040 |
Why?
|
| Cytokines | 2 | 2014 | 1272 | 0.030 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 25 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 86 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2826 | 0.030 |
Why?
|
| Gene Order | 1 | 2015 | 78 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 84 | 0.030 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2014 | 9 | 0.030 |
Why?
|
| Luciferases, Firefly | 1 | 2014 | 14 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 93 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2014 | 59 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 222 | 0.030 |
Why?
|
| Dimerization | 1 | 2014 | 144 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 74 | 0.030 |
Why?
|
| Cell Separation | 1 | 2015 | 237 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 296 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 312 | 0.030 |
Why?
|
| Teratoma | 1 | 2015 | 125 | 0.030 |
Why?
|
| Receptors, Antigen | 1 | 2013 | 33 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 230 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 351 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 1889 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 229 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 82 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 391 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2014 | 887 | 0.030 |
Why?
|
| Organoids | 1 | 2016 | 275 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 347 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 816 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2015 | 810 | 0.030 |
Why?
|
| Mesothelioma | 1 | 2013 | 78 | 0.030 |
Why?
|
| Cell Movement | 1 | 2015 | 838 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1679 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1354 | 0.020 |
Why?
|
| Blood Donors | 1 | 2011 | 62 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 712 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 124 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 468 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 3074 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2013 | 646 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2311 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 517 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 138 | 0.020 |
Why?
|
| Antibodies | 1 | 2009 | 371 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2008 | 119 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1935 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 650 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2011 | 745 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2674 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 4151 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 508 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 1213 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2011 | 3770 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 2029 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 3657 | 0.010 |
Why?
|
| Male | 2 | 2015 | 59522 | 0.010 |
Why?
|